A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-02. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
The PAH world hypothesis is a speculative hypothesis that proposes that polycyclic aromatic hydrocarbons (PAHs), known to be abundant in the universe, including in comets, and assumed to be abundant in the primordial soup of the early Earth, played a major role in the origin of life by mediating the synthesis of RNA molecules, leading into the RNA world. However, as yet, the hypothesis is untested.
== Medical uses == Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression. Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
6 May – Terence Etherton, Baron Etherton, 73, British judge and politician, Master of the Rolls (2016–2021), chancellor of the High Court (2013–2016), and member of the House of Lords (since 2021). 20 May – Patrick O'Flynn, 59, British journalist (Daily Express) and politician, MEP (2014–2019), cancer. (death announced on this date) 13 June – Seán Neeson, 79, Northern Irish politician, MLA (1982–1986, 1998–2011). 1 July – David Lipsey, Baron Lipsey, 77, British journalist and life peer (since 1999). 7 July – Norman Tebbit, Baron Tebbit, 94, British politician, secretary of state for employment (1981–1983), chancellor of the Duchy of Lancaster (1985–1987), and MP (1970–1992). 9 July – Ian Blair, Baron Blair of Boughton, 72, British police officer and life peer, Commissioner of Police of the Metropolis (2005–2008), member of the House of Lords (since 2010). 13 July – Mark Schreiber, Baron Marlesford, 93, British politician, member of the House of Lords (since 1991). 17 July – Tommy Gallagher, 82, Northern Irish politician, MLA (1998–2011). (death announced on this date) 18 July – David Alliance, Baron Alliance, 93, Iranian-born British businessman, member of the House of Lords (2004–2025). 22 July – Sir Jamie McGrigor, 6th Baronet, 75, Scottish politician, MSP (1999–2016). (death announced on this date) 29 July – Meghnad Desai, Baron Desai, 85, Indian-born British economist and politician, member of the House of Lords (since 1991). 3 August – Stella Rimington, 90, British author and Director General of MI5 (1992–1996).
Sources: en.wikipedia.org
According to Democracy Now!, "[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug." The lawsuits also accused Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. Nigerian medical personnel as well as at least one Pfizer physician said the trial was conducted without regulatory approval. In 2007, Pfizer published a Statement of Defense letter, claiming that Trozan was safely tested in five thousand patients prior to the Nigerian children clinical trial, and mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics. They claim that the effects suffered by the victims were due to meningitis and not Trovan. Pfizer states that its actions did not violate any law, as there was no law in Nigeria that requires ethical committee approval prior to conducting a clinical trial. However, the drug was never tested in children before. Pfizer claims that no unusual side effects, unrelated to meningitis, were observed after four weeks in the Nigerian children clinical study, though an investigation by The Washington Post revealed that one of the children continued to have the drug administered to them until their death despite their condition worsening, which violated ethical guidelines.
==== 2026 Iran war ==== Kiggans has strongly supported the Trump administration in the 2026 Iran war, also known as Operation Epic Fury. Kiggans stated in March 2026 that the goals of the war include "destroying Iran's ballistic missile capability, destroying their navy, and destroying their ability to have nuclear weapons." In June 2026, Kiggans voted against a war powers resolution that would have limited the president's ability to wage war in Iran without congressional consent.
== Election process == The president is not directly elected by Burmese voters; instead, they are indirectly elected by the Presidential Electoral College (သမ္မတရွေးချယ်တင်မြှောက်ရေးအဖွဲ့), an electoral body made of three separate committees. One committee is composed of MPs who represent the proportions of MPs elected from each Region or State; another is composed of MPs who represent the proportions of MPs elected from each township population; the third is of military-appointed MPs personally nominated by the Defence Services' commander-in-chief. Each of the three committees nominates a presidential candidate. Afterward, all the Pyidaungsu Hluttaw MPs vote for one of three candidates—the candidate with the highest number of votes is elected president, while the other two are elected as vice-presidents. The president serves for a term of 5 years. Should a president resign for any reason or die in office, the Presidential Electoral College will meet and each of the three committees will nominate a candidate to finish out the prior President's term so that the terms of the legislature and presidency are synchronised. The candidate who receives the most votes from the nominees is elected. This process is similar to the one prescribed by the 1947 Constitution, in which MPs from the Parliament's Chamber of Nationalities and Chamber of Deputies elected the president by secret ballot. The President was then responsible for appointing a prime minister (on the advice of the Chamber of Deputies), who was constitutionally recognised as the head of government and led the Cabinet.
==== Carotenosis ==== Carotenoderma, also referred to as carotenemia, is a benign and reversible medical condition where an excess of dietary carotenoids results in orange discoloration of the outermost skin layer. It is associated with a high blood β-carotene value. This can occur after a month or two of consumption of β-carotene rich foods, such as carrots, carrot juice, tangerine juice, mangos, or in Africa, red palm oil. β-carotene dietary supplements can have the same effect. The discoloration extends to palms and soles of feet, but not to the white of the eye, which helps distinguish the condition from jaundice. Consumption of greater than 30 mg/day for a prolonged period has been confirmed as leading to carotenemia.
Sources: en.wikipedia.org
==== Affixes ==== Prefixes and suffixes, primarily in Greek—but also in Latin, have a droppable -o-. As a general rule, this vowel almost always acts as a joint-stem to connect two consonantal roots (e.g. arthr- + -o- + -logy = arthrology), but generally, the -o- is dropped when connecting to a vowel-stem (e.g. arthr- + -itis = arthritis, instead of arthr-o-itis). Generally, Greek prefixes go with Greek suffixes and Latin prefixes with Latin suffixes. Although it is technically considered acceptable to create hybrid words, it is strongly preferred in coining new terms not to mix different lingual roots. Examples of accepted medical words that do mix lingual roots are neonatology and quadriplegia. Prefixes do not normally require further modification to be added to a word root because the prefix normally ends in a vowel or vowel sound, although in some cases they may assimilate slightly and an in- may change to im- or syn- to sym-. Suffixes are attached to the end of a word root to add meaning such as condition, disease process, or procedure. Suffixes are categorized as either (1) needing the combining form, or (2) not needing the combining form since they start with a vowel.
=== International normalized ratio === The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed. This is due to the variations between different types and batches of manufacturer's tissue factor used in the reagent to perform the test. The INR was devised to standardize the results. Each manufacturer assigns an ISI value (International Sensitivity Index) for any tissue factor they manufacture. The ISI value indicates how a particular batch of tissue factor compares to an international reference tissue factor. The ISI is usually between 0.94 and 1.4 for more sensitive and 2.0–3.0 for less sensitive thromboplastins. The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used.
== External links == Newspaper clippings about Prince August Wilhelm of Prussia in the 20th Century Press Archives of the ZBW Information about Prince August Wilhelm of Prussia in the Reichstag database
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.